Oxprenolol, sold under the brand name Trasicor among others, is a non-selective beta blocker with some intrinsic sympathomimetic activity. It is used for the treatment of angina pectoris, abnormal heart rhythms, and high blood pressure. Chemically an aryloxypropanolamine with a chiral center, oxprenolol antagonizes beta1 and beta2 adrenergic receptors while exhibiting partial agonist activity at the same receptors, which can reduce resting bradycardia compared with pure antagonists. It is commonly administered orally as a racemate, is well absorbed with variable oral bioavailability due to first pass hepatic metabolism, and is eliminated by hepatic biotransformation with renal excretion of metabolites. Clinically it reduces heart rate, myocardial contractility, and myocardial oxygen demand and may cross the blood brain barrier to produce central nervous system effects in susceptible patients. Typical pharmaceutical formulations and dosing regimens are selected to balance antihypertensive and antianginal efficacy with tolerability, and dose adjustments are recommended in hepatic impairment.
Parent: Oxprenolol
Typical active pharmaceutical ingredient quality control specifications for oxprenolol include assay by validated method with target content commonly in the range of 98.0 to 102.0 percent of stated amount, individual related substances typically limited to not more than 0.2 percent each, unspecified impurities typically limited to not more than 0.1 percent each, and total impurities generally limited to not more than 1.0 percent. Related compounds encountered in manufacture and stability studies commonly include N-dealkylated and other minor oxidative or hydrolytic degradation products, trace amounts of synthetic precursors or intermediates, and stereoisomeric impurities; specified impurities are controlled at the individual limits above and summed to meet the total impurity limit. Additional quality parameters frequently applied are limits for heavy metals for example not more than 20 parts per million and control of residual solvents in accordance with ICH Q3C classification and limits appropriate to the solvent class.
Oxprenolol is used to treat angina pectoris, certain cardiac arrhythmias, and hypertension by blocking beta adrenergic receptors, reducing heart rate, contractility, and myocardial oxygen demand.
Use in pregnancy requires careful assessment of risks and benefits by a clinician; beta blockers can be associated with fetal growth restriction and neonatal effects when used in pregnancy, so oxprenolol should only be used if clearly needed and under medical supervision.
Yes, Oxprenolol exhibits intrinsic sympathomimetic activity and functions as a partial agonist at beta adrenergic receptors, producing some receptor activation while also blocking full agonist effects.
Oxprenolol is moderately lipophilic, a property that facilitates oral absorption and enables some central nervous system penetration.
